CAPR Capricor Therapeutics Inc
Company Analysis
Latest News
🟢 Capricor Therapeutics is trading 6.61% up today after Piper Sandler upgrade to Overweight
Capricor Therapeutics is trading 6.61% up now at $10.56 after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $25...
🟢 Capricor Therapeutics is trading 5.5% up today
Capricor Therapeutics is trading 5.53% up now at $10.12, but no new company-specific announcement clearly explains the August 31, 2026 move. - Recent...
🔴 Capricor Therapeutics is trading 5% down today after a securities-fraud class-action announcement
Capricor Therapeutics is trading at $9.55, down 5.02%, after an investor-law-firm announcement publicized a securities-fraud class action and September 28,...
🟢 Capricor Therapeutics is trading 13.03% up today after the FDA extended deramiocel’s PDUFA target date
Capricor Therapeutics is trading 13.03% up now at $10.58 after the FDA extended deramiocel’s PDUFA target date from August 22 to November 22, 2026. - The...
🟢 Capricor Therapeutics is trading 5.77% up today after FDA moves deramiocel’s PDUFA deadline
Capricor Therapeutics is trading at $9.90, up 5.77%, extending a sharp multi-session rebound after the FDA moved deramiocel’s PDUFA deadline to November 22,...
🟢 Capricor Therapeutics is trading 14.96% up today on deramiocel PDUFA deadline extension
Capricor Therapeutics is trading at $9.53 (+14.96%) after the FDA extended deramiocel’s PDUFA deadline to November 22, 2026, allowing review of new HOPE-3 data...
🟢 Capricor Therapeutics is trading 9.83% up today after FDA extended deramiocel review to November 2026
Capricor Therapeutics is trading 9.83% up at $9.11 as investors continue reacting to the FDA’s August 24 decision to extend deramiocel’s PDUFA deadline to...
🟢 Capricor Therapeutics is trading 21.62% up today after FDA extended deramiocel's decision deadline
Capricor Therapeutics is trading 21.62% up now at $8.27 after the FDA extended deramiocel’s decision deadline to November 22, 2026. - The three-month reprieve...
Capricor's Duchenne Therapy Gets a Three-Month FDA Reprieve — But Can Extra Data Overcome a Brutal Advisory Vote?
Shares of Capricor Therapeutics (CAPR) surged as much as 29% Monday before settling at $7.40 (+8.9%) after the company disclosed that the FDA pushed its...
🟢 Capricor Therapeutics is trading 9% up in pre-market after FDA extends Deramiocel PDUFA date
Capricor Therapeutics is trading at $7.40 (+8.88%) after the FDA extended Deramiocel’s PDUFA date from August 22 to November 22, 2026, allowing additional time...
Capricor Announces FDA Extends PDUFA Date for DMD Therapy Deramiocel to November 2026
Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has extended the PDUFA target action date for its Biologics License...
🟢 Capricor Therapeutics is trading 11.29% up today after FDA extends deramiocel PDUFA date
Capricor Therapeutics is trading 11.29% up now at $7.00 after the FDA extended deramiocel’s PDUFA target action date from August 22, 2026, to November 22,...
🟢 Capricor Therapeutics is trading 10.33% up in pre-market with no newly identified company-specific catalyst
Capricor Therapeutics is trading at $6.94, up 10.33% in pre-market on August 24, 2026, with no newly identified company-specific announcement explaining the...
🟢 Capricor Therapeutics is trading 5.7% up in pre-market with no clear company-specific catalyst
Capricor Therapeutics is trading 5.7% up at $6.65, with no new company-specific announcement clearly explaining the August 24 pre-market rise. - The stock had...
🔴 Capricor Therapeutics is trading 10.1% down today after securities-fraud class-action announcements
Capricor Therapeutics is trading 10.1% down now at $6.14 after new securities-fraud class-action announcements and activist investor Kaos Capital’s demand for...
🔴 Capricor Therapeutics is trading 7.52% down today amid new securities fraud class actions and activist investor pressure ahead of FDA’s August 22, 2026 Deramiocel decision
- Capricor Therapeutics is trading at $6.32 (-7.52%) ahead of the FDA’s August 22, 2026 Deramiocel decision, following a previous 9-3 vote by advisers against...
🔴 Capricor Therapeutics is trading 10.65% down today ahead of FDA’s August 22 decision
Capricor Therapeutics is trading 10.65% down at $7.13 as investors reassess Deramiocel’s approval prospects ahead of the FDA’s August 22 decision. - The...
🔴 Capricor Therapeutics is trading 5.16% down today amid biotech-sector weakness
Capricor Therapeutics is trading 5.16% down at $7.57 amid a 2.47% drop in biotech stocks and broader market weakness as Treasury yields rise. - It followed a...
🟢 Capricor Therapeutics is trading 10.59% up today as biotech shares rally broadly
Capricor Therapeutics is trading 10.59% up now at $7.83 as biotechnology shares rally broadly. - Investors await the August 22 FDA decision for deramiocel;...
🟢 Capricor Therapeutics is trading 9.18% up today as biotechnology shares rally broadly
Capricor Therapeutics is trading 9.18% up now at $7.73 as biotechnology shares rally broadly. - Positive sector momentum appears to be supporting the move. -...